Cargando…

Testosterone therapy and bone quality in men with diabetes and hypogonadism: Study design and protocol

CONTEXT: Type 2 diabetes mellitus (T2D) is often accompanied by male hypogonadism and both conditions are associated with increased risk for fractures. Testosterone (T) has been shown to improve the bone health of hypogonadal men but has not been tested in patients who also have T2D in addition to l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Russo, Vittoria, Colleluori, Georgia, Chen, Rui, Mediwala, Sanjay, Qualls, Clifford, Liebschner, Michael, Villareal, Dennis T., Armamento-Villareal, Reina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933702/ https://www.ncbi.nlm.nih.gov/pubmed/33718653 http://dx.doi.org/10.1016/j.conctc.2021.100723

Ejemplares similares

Adipocytes ESR1 Expression, Body Fat and Response to Testosterone Therapy in Hypogonadal Men Vary According to Estradiol Levels
por: Colleluori, Georgia, et al.
Publicado: (2018)

MON-094 Aromatase Inhibitors and Weight Loss in Severely Obese Male Veterans with Hypogonadism: A Randomized Clinical Trial
por: Colleluori, Georgia, et al.
Publicado: (2019)

Aromatase Inhibitors Plus Weight Loss Improves the Hormonal Profile of Obese Hypogonadal Men Without Causing Major Side Effects
por: Colleluori, Georgia, et al.
Publicado: (2020)

Baseline Testosterone Predicts Body Composition and Metabolic Response to Testosterone Therapy
por: Deepika, FNU, et al.
Publicado: (2022)

OR25-6 In Men on Testosterone Therapy, Baseline Testosterone Level of <264 ng/dL is Associated with Greater Improvement in Body Composition, While Level of ≥264 ng/dL Favors Improvement in Metabolic Profile
por: Aguirre, Lina, et al.
Publicado: (2022)

OR27-01 Upregulated Prdm16 Impairs Adipogenesis And Promotes Myogenesis Via PAX7 And Osteogenesis In Testosterone-treated Hypogonadal Men
por: Bathina, Siresha, et al.
Publicado: (2023)

Hypogonadism, Type-2 Diabetes Mellitus, and Bone Health: A Narrative Review
por: Russo, Vittoria, et al.
Publicado: (2021)

Fat Mass Follows a U-Shaped Distribution Based on Estradiol Levels in Postmenopausal Women
por: Colleluori, Georgia, et al.
Publicado: (2018)

Hemoglobin A1c Threshold for Reduction in Bone Turnover in Men With Type 2 Diabetes Mellitus
por: Joad, Sabaa, et al.
Publicado: (2021)

MON-382 Bone Quality and Strength in Obese Men with Type 2 Diabetes Mellitus Are Impaired and Negatively Influenced by Adiposity
por: Vigevano, Francesca, et al.
Publicado: (2020)

Hemoglobin A1c of 7% is the Threshold For Bone Impairment in Men With Type 2 Diabetes Mellitus
por: Joad, Sabaa Salim, et al.
Publicado: (2021)

ODP101 In Men with Type 2 Diabetes Mellitus, Poor Glycemic Control is Associated with Diminished Circulating Osteoblast Progenitors
por: Ballato, Elliot, et al.
Publicado: (2022)

Circulating osteogenic progenitors and osteoclast precursors are associated with long-term glycemic control, sex steroids, and visceral adipose tissue in men with type 2 diabetes mellitus
por: Ballato, Elliot, et al.
Publicado: (2022)

Effect of Weight Loss, Exercise, or Both on Undercarboxylated Osteocalcin and Insulin Secretion in Frail, Obese Older Adults
por: Colleluori, Georgia, et al.
Publicado: (2017)

SUN-541 Effect of Testosterone Replacement Therapy Added to Intensive Lifestyle Intervention in Frail, Older Male Veterans with Hypogonadism and Obesity: A Randomized Clinical Trial
por: Barnouin, Yoann, et al.
Publicado: (2020)

Weight Loss, Exercise, or Both and Cardiometabolic Risk Factors in Obese Older Adults: Results of a Randomized Controlled Trial
por: Bouchonville, Matthew, et al.
Publicado: (2013)

Fat, Muscle, and Bone Interactions in Obesity and the Metabolic Syndrome
por: Armamento-Villareal, Reina, et al.
Publicado: (2014)

Indices of sarcopenic obesity are important predictors of finite element analysis-derived bone strength in older adults with obesity
por: Gregori, Giulia, et al.
Publicado: (2023)

OR02-05 Effect of Testosterone Replacement Therapy Added to Intensive Lifestyle Intervention on Cognitive Functions in Frail, Older Veterans with Hypogonadism and Obesity: A Randomized Clinical Trial
por: Gregori, Giulia, et al.
Publicado: (2020)

Testosterone and Adipokines are Determinants of Physical Performance, Strength, and Aerobic Fitness in Frail, Obese, Older Adults
por: Aguirre, Lina E., et al.
Publicado: (2014)

The complex pathophysiology of bone fragility in obesity and type 2 diabetes mellitus: therapeutic targets to promote osteogenesis
por: Bathina, Siresha, et al.
Publicado: (2023)

Sarcopenic Obesity Indices Are Major Determinants of Bone Strength in Older Adults With Obesity
por: Gregori, Giulia, et al.
Publicado: (2021)

Novel Adipokines and Their Role in Bone Metabolism: A Narrative Review
por: Deepika, Fnu, et al.
Publicado: (2023)

SUN-LB69 A Comparison Between Weight Loss Associated Bone Loss From Lifestyle Measures Versus Bariatric Surgery
por: La, Betty, et al.
Publicado: (2020)

The rs4646 and rs12592697 Polymorphisms in CYP19A1 Are Associated with Disease Progression among Patients with Breast Cancer from Different Racial/Ethnic Backgrounds
por: Armamento-Villareal, Reina, et al.
Publicado: (2016)

Testosterone Replacement Therapy and Bone Mineral Density in Men with Hypogonadism
por: Kim, Se Hwa
Publicado: (2014)

110. Bone Mineral Density Screening in Veterans Living with HIV
por: Khanjee, Naveed, et al.
Publicado: (2020)

Testosterone replacement in male hypogonadism
por: Kalra, Sanjay, et al.
Publicado: (2010)

Heightened levels of plasma growth differentiation factor 15 in men living with HIV
por: Agarwal, Neeti, et al.
Publicado: (2022)

Cognitive effects of testosterone and finasteride administration in older hypogonadal men
por: Borst, Stephen E, et al.
Publicado: (2014)

Testosterone versus clomiphene citrate in managing symptoms of hypogonadism in men
por: Dadhich, Pranav, et al.
Publicado: (2017)

Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy
por: Ide, Veerle, et al.
Publicado: (2020)

PMON260 Cost-Effectiveness of Testosterone Treatment for Men with Hypogonadism
por: Jayasena, Channa, et al.
Publicado: (2022)

A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men
por: Swerdloff, Ronald S, et al.
Publicado: (2020)

Optimal injection interval for testosterone undecanoate treatment of hypogonadal and transgender men
por: Shankara Narayana, Nandini, et al.
Publicado: (2021)

Long-term testosterone replacement therapy reduces fatigue in men with hypogonadism
por: de Almeida Ferreira, Maurício, et al.
Publicado: (2022)

Hypogonadotropic hypogonadism in human immunodeficiency virus-infected men: uncommonly low testosterone levels
por: Gomes, Ana Coelho, et al.
Publicado: (2017)

Corrigendum for: “A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men”
Publicado: (2020)

Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss
por: Yassin, AA, et al.
Publicado: (2013)

Morning free and total testosterone in HIV-infected men: implications for the assessment of hypogonadism
por: Monroe, Anne K, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4dtuonaj4i19urks9cde1emj6r